Health Economics Review (Sep 2021)

The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

  • Andreia Borges,
  • Filipa Pereira,
  • Patrícia Redondo,
  • Luís Antunes,
  • Cláudia Vieira,
  • Pedro Antunes,
  • Maria José Bento,
  • Susana Sousa,
  • José Machado Lopes,
  • Francisco Rocha-Gonçalves,
  • Joaquim Abreu de Sousa,
  • Deolinda Sousa Pereira,
  • Marina Borges

DOI
https://doi.org/10.1186/s13561-021-00332-0
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

Highlights i. The results obtained in the AC-DHP cohort, which included Pertuzumab as a NeoT, suggest better clinical outcomes compared to the AC-DH group, a confirmation based on real-world data. ii. Some patient profiles seem to be more promising concerning the overall costs for pathological complete response, but the present data does not include a long-term follow-up period, which suggests that interpretations should be performed with caution. iii. Pertuzumab cost estimated represented a great proportion of overall total costs per patient, but further research (including the costs of the whole episode of care) and continuously monitoring (additional RWE) is needed for a more robust cost-effectiveness analysis.

Keywords